#China #Shenzhen #EY Entrepreneur #Chipscreen Biosciences #Lu Xianping

Dr. Lu Xianping: A Trailblazer in Pharmaceuticals

On December 5, 2025, Dr. Lu Xianping, the founder and chairman of Shenzhen Chipscreen Biosciences Co., Ltd., was honored as the winner of the EY Entrepreneur Of The Year™ 2025 in the Chinese mainland category. This accolade celebrates his exceptional contributions to the advancement of innovative drug development and the enhancement of healthcare accessibility in China.

Esteemed as a key figure in the innovative pharmaceutical sector, Dr. Lu has made a profound impact through his pioneering work in developing new drug therapies. After earning his Ph.D. in Molecular Biology from Peking Union Medical College and completing postdoctoral research in the United States, Dr. Lu returned to China with a mission: to create affordable, innovative drugs that could enhance the quality of life for the general population.

In 2001, he established Chipscreen Biosciences with this noble vision in mind. At a time when the Chinese pharmaceutical market was predominantly focused on generic medications, Dr. Lu chose to carve a different path. He dedicated his efforts to pioneering first-in-class drugs characterized by novel mechanisms of action. Notably, under his leadership, Chipscreen's Chidamide became the first original small-molecule anti-tumor innovative drug in China and the first of its kind to be globally licensed out. This milestone provided a significant treatment option for patients with peripheral T-cell lymphoma and other malignancies, offering renewed hope for those affected by these challenging diseases.

Furthermore, Dr. Lu's development of Chiglitazar Sodium, the world’s first PPAR pan-agonist for Type 2 diabetes, marked a historic step in pharmaceutical innovation. Both drugs are now included in China's National Reimbursement Drug List (NRDL), significantly alleviating financial burdens faced by patients across the nation.

His commitment extends beyond product development. Dr. Lu has been an advocate for enhancing the pharmaceutical landscape in China, encouraging improvements in drug approval processes and capital market reforms that favor innovation. Under his guidance, Chipscreen Biosciences has contributed more than RMB 700 million in medicines, assisting over 10,000 patients in reducing their treatment expenses.

As multiple new drug candidates with first-in-class potential are on the horizon, Dr. Lu’s work continues to focus on addressing significant health challenges, including chronic diseases such as Alzheimer’s disease. His vision remains steadfast: to provide cutting-edge therapeutic options that can make a real difference in patients' lives.

The EY Entrepreneur Of The Year™ award ceremony, themed “Two Decades of Unwavering Strength, Forging Ahead in the New Era,” recognized Dr. Lu’s pivotal role in fostering national economic growth and social advancement. His journey stands as a testament to what can be achieved with passion, innovation, and an unwavering commitment to improving the health and well-being of society.

In conclusion, Dr. Lu Xianping's recognition as a prominent entrepreneur highlights his remarkable achievements and dedication to pharmaceutical innovation. As he continues to navigate the path of drug discovery and development, the medical community and patients alike eagerly anticipate the new horizons his work will unveil. His story is not just about success in business—it is about making a tangible impact on people's lives through groundbreaking medical advancements.